TY - JOUR
T1 - Characterization of Specific Opioid Binding Sites in Neural Membranes from the Myenteric Plexus of Porcine Small Intestine
AU - Townsend IV, De Wayne
AU - Portoghese, Philip S.
AU - Brown, David R.
PY - 2004/1
Y1 - 2004/1
N2 - δ- and κ-Opioid receptors (OPRs), but not μ-OPRs, are expressed in the myenteric plexus of the porcine distal small intestine. In a subpopulation of myenteric neurons, δ- and κ-OPRs seem to be colocalized and may functionally interact. In this study, radioligand binding was used to characterize myenteric OPR populations in detail. The nonselective OPR antagonist [3H]diprenorphine bound to a single, high-affinity site in myenteric neural membrane homogenates. Naloxone displaced 65 and 59% of [3H]diprenorphine binding from this site in Na+-free Tris and Krebs-HEPES buffers, respectively. Naltrexone-derived δ- and κ-OPR antagonists, including naltriben, 7-benzylidenenaltrexone, nor-binaltorphimine, and 5′-guanidinonaltrindole, displaced [ 3H]diprenorphine from two distinct binding sites to levels similar to that of naloxone. The selective δ-OPR ligands Tyr-1,2,3,4-tetrahydroisoquinoline-Phe-Phe-OH (TIPP), [D-Pen 2,D-Pen5]enkephalin (DPDPE), [D-Ala2, Glu 4]deltorphin II, and (+)-4-[(αR)-α ((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl)-N, N-diethylbenzamide (SNC-80) and the κ-OPR agonist (D-(5α,7α ,8β)-(-)-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxoaspiro-(4,5)dec-8-yl) benzeneacetamide (U-69,593) displaced [3H]diprenorphine from three independent binding sites; these included high-affinity δ- and κ-OPR sites, and a residual binding site. Residual [ 3H]diprenorphine binding was displaced by the selective κ-OPR antagonist nor-binaltorphimine after saturation of δ and κ sites, respectively, with DPDPE and U-69,593. The residual binding site displayed low affinity for δ- and κ-OPR agonists and TIPP, as well as moderate affinity for naltrexone-derived ligands, properties reminiscent of δ-/κ-OPR heterodimers.
AB - δ- and κ-Opioid receptors (OPRs), but not μ-OPRs, are expressed in the myenteric plexus of the porcine distal small intestine. In a subpopulation of myenteric neurons, δ- and κ-OPRs seem to be colocalized and may functionally interact. In this study, radioligand binding was used to characterize myenteric OPR populations in detail. The nonselective OPR antagonist [3H]diprenorphine bound to a single, high-affinity site in myenteric neural membrane homogenates. Naloxone displaced 65 and 59% of [3H]diprenorphine binding from this site in Na+-free Tris and Krebs-HEPES buffers, respectively. Naltrexone-derived δ- and κ-OPR antagonists, including naltriben, 7-benzylidenenaltrexone, nor-binaltorphimine, and 5′-guanidinonaltrindole, displaced [ 3H]diprenorphine from two distinct binding sites to levels similar to that of naloxone. The selective δ-OPR ligands Tyr-1,2,3,4-tetrahydroisoquinoline-Phe-Phe-OH (TIPP), [D-Pen 2,D-Pen5]enkephalin (DPDPE), [D-Ala2, Glu 4]deltorphin II, and (+)-4-[(αR)-α ((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl)-N, N-diethylbenzamide (SNC-80) and the κ-OPR agonist (D-(5α,7α ,8β)-(-)-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxoaspiro-(4,5)dec-8-yl) benzeneacetamide (U-69,593) displaced [3H]diprenorphine from three independent binding sites; these included high-affinity δ- and κ-OPR sites, and a residual binding site. Residual [ 3H]diprenorphine binding was displaced by the selective κ-OPR antagonist nor-binaltorphimine after saturation of δ and κ sites, respectively, with DPDPE and U-69,593. The residual binding site displayed low affinity for δ- and κ-OPR agonists and TIPP, as well as moderate affinity for naltrexone-derived ligands, properties reminiscent of δ-/κ-OPR heterodimers.
UR - http://www.scopus.com/inward/record.url?scp=0345866766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345866766&partnerID=8YFLogxK
U2 - 10.1124/jpet.103.058016
DO - 10.1124/jpet.103.058016
M3 - Article
C2 - 14569065
AN - SCOPUS:0345866766
SN - 0022-3565
VL - 308
SP - 385
EP - 393
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -